Skip to main content

Table 2 ORs and 95% CIs for HPV-16 positive ICC according to HLA.

From: Interaction between polymorphisms of the Human Leukocyte Antigen and HPV-16 Variants on the risk of invasive cervical cancer

 

Controls

(n = 257)

HPV-16 Cases

(n = 112)

HLA

  

Crude

Adjustedd

 

C/Na

C/N

ORb

OR

CIc

DQA1

     

*0102

80/177

39/73

1.18

1.22

0.73–2.04

DQB1

     

*0501

71/186

25/87

0.75

0.72

0.40–1.27

   *06

87/170

46/66

1.36

1.32

0.80–2.17

*0602

44/213

30/82

1.77

1.59

0.89–2.83

DRB1

     

   *01

52/205

22/90

0.96

0.89

0.49–1.64

*0102

29/228

12/100

0.94

0.83

0.38–1.79

   *04

74/183

23/89

0.64

0.67

0.38–1.19

   *13

61/196

19/93

0.66

0.78

0.42–1.45

*1302

27/230

4/108

0.32

0.43

0.14–1.32

DRB1-DQB1 haplotypes

     

   0102–0501

29/228

12/100

0.94

0.59

0.23–1.51

   15-0602

33/224

28/84

2.26

2.12

1.15–3.93

   1503-0602

14/243

15/97

2.68

2.77

1.20–6.39

   08041-0301

5/252

3/109

1.39

0.88

0.14–5.47

   09012-0201/02

3/254

3/109

2.33

3.02

0.56–16.29

  1. a) C/N: Carriers/Non carriers;
  2. b) OR: Odds Ratio;
  3. c) CI: Confidence Interval;
  4. d) Adjusted for age and ethnic group.